Publications

• Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis.

  (Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M.) Blood Cancer J. 2019 12 03;9(12):97 PMID: 31796726 PMCID: PMC6890709 SCOPUS ID: 2-s2.0-85075936084 12/05/2019

• Comment: Is There a Role for Allogenic Hematopoietic Cell Transplantation in Primary Mediastinal Large B Cell Lymphoma?

  (Fenske TS.) Biol Blood Marrow Transplant. 2019 12;25(12):e354-e355 PMID: 31614199 10/16/2019

• Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis.

  (Badar T, Khan MA, Szabo A, Drobyski W, Chhabra S, Dhakal B, Fenske TS, Hamadani M, Hari P, Jerkins JH, Shah NN, Shaw BE, D'Souza A.) Amyloid. 2019 Dec;26(4):210-215 PMID: 31347424 SCOPUS ID: 2-s2.0-85074118154 07/28/2019

• Contemporary Outcomes for Advanced-Stage Classical Hodgkin Lymphoma in the U.S.: Analysis of Surveillance, Epidemiology, and End Results Database.

  (Guru Murthy GS, Szabo A, Hamadani M, Fenske TS, Shah NN.) Oncologist. 2019 11;24(11):1488-1495 PMID: 31467178 PMCID: PMC6853108 SCOPUS ID: 2-s2.0-85071466837 08/31/2019

• Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.

  (Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, Fenske TS, Shea TC, Barr PM, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM.) Blood Adv. 2019 10 22;3(20):3132-3135 PMID: 31648328 PMCID: PMC6849956 10/28/2019

• Measurement of circulating tumor DNA to guide management of patients with lymphoma.

  (Sriram D, Lakhotia R, Fenske TS.) Clin Adv Hematol Oncol. 2019 Sep;17(9):509-517 PMID: 31549972 09/25/2019

• Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.

  (Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M.) Biol Blood Marrow Transplant. 2019 09;25(9):1859-1868 PMID: 31132455 PMCID: PMC6755039 SCOPUS ID: 2-s2.0-85067280149 05/28/2019

• Factors Associated With Unplanned 30-Day Readmissions After Hematopoietic Cell Transplantation Among US Hospitals.

  (Dhakal B, Giri S, Levin A, Rein L, Fenske TS, Chhabra S, Shah NN, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani M.) JAMA Netw Open. 2019 07 03;2(7):e196476 PMID: 31276175 SCOPUS ID: 2-s2.0-85068511187 07/06/2019

• Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation.

  (Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Saini NY, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen AF, Fenske TS.) Blood Adv. 2019 06 11;3(11):1661-1669 PMID: 31167818 PMCID: PMC6560348 SCOPUS ID: 2-s2.0-85067501987 06/07/2019

• Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT.

  (Kanate AS, Kumar A, Dreger P, Dreyling M, Le Gouill S, Corradini P, Bredeson C, Fenske TS, Smith SM, Sureda A, Moskowitz A, Friedberg JW, Inwards DJ, Herrera AF, Kharfan-Dabaja MA, Reddy N, Montoto S, Robinson SP, Abutalib SA, Gisselbrecht C, Vose J, Gopal A, Shadman M, Perales MA, Carpenter P, Savani BN, Hamadani M.) JAMA Oncol. 2019 May 01;5(5):715-722 PMID: 30816957 PMCID: PMC6988125 03/01/2019

• Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.

  (Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros LJ, Wang MI, Cohen JB, Calzada O, Churnetski MC, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast MA, Fenske TS, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns TF, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK.) J Clin Oncol. 2019 02 20;37(6):471-480 PMID: 30615550 PMCID: PMC7554677 01/08/2019

• Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis.

  (Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M.) J Hematol Oncol. 2019 01 10;12(1):6 PMID: 30630534 PMCID: PMC6329157 SCOPUS ID: 2-s2.0-85059829766 01/12/2019